Medicus Pharma sees appointment of Dr Huma Qamar as key to company̢۪s future
November 17, 2023 at 01:23 pm EST
Share
(via NewsDirect)
In an exclusive interview with Dr Huma Qamar, chief scientific officer for Medicus Pharma Ltd, exciting developments in skincare and oncology are discussed.
Dr Qamar shares her passion for addressing unmet medical needs, particularly in the field of basal cell carcinoma.
The focus is on SkinJet, a flagship company acquired by Medicus Pharma, utilizing revolutionary microarray needles. The needles, transdermally delivering the chemotherapeutic agent doxorubicin, show promising data in preventing relapse and remission of basal cell carcinoma.
Looking ahead, Dr Qamar outlines the company's goals for 2024, emphasizing the resumption of clinical development activities and recruitment efforts. The aim is to complete the phase two trial and present promising data.
Dr Qamar, driven by a dedication to oncology and patient well-being, discusses the emotional impact of cancer and the hope that Medicus Pharma's contributions will bring positive changes to the lives of patients.
Contact Details
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company focused on investing in novel life sciences and bio-technology companies through Food and Drug Administration (FDA) approved clinical trials. The Company identifies, acquires and advances relatively de-risked clinical stage assets through clinical development and commercialization. The Company is exploring to expand its drug development pipeline through acquisitions and partnerships. The Company, through its subsidiary, SkinJect, Inc., is focused on the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of certain skin cancers. SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma.